Ledyard National Bank Buys 196 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Ledyard National Bank lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,144 shares of the medical research company’s stock after acquiring an additional 196 shares during the period. Ledyard National Bank’s holdings in Thermo Fisher Scientific were worth $1,669,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in TMO. Raleigh Capital Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 49.1% during the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after purchasing an additional 27 shares in the last quarter. Cedar Mountain Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 107.0% during the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after purchasing an additional 46 shares in the last quarter. Operose Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 250.0% during the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock worth $53,000 after purchasing an additional 75 shares in the last quarter. Financial Connections Group Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $53,000. Finally, Valley National Advisers Inc. grew its holdings in shares of Thermo Fisher Scientific by 40.5% during the 3rd quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock worth $56,000 after purchasing an additional 32 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Up 0.6 %

NYSE:TMO traded up $3.27 on Monday, reaching $576.87. The company’s stock had a trading volume of 962,347 shares, compared to its average volume of 1,554,585. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The firm has a market cap of $220.20 billion, a PE ratio of 37.00, a PEG ratio of 2.41 and a beta of 0.80. The business’s 50-day moving average price is $574.18 and its two-hundred day moving average price is $531.06.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.56 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Analyst Upgrades and Downgrades

Several analysts recently commented on TMO shares. Raymond James boosted their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Deutsche Bank Aktiengesellschaft boosted their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday. Royal Bank of Canada boosted their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. The Goldman Sachs Group boosted their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Finally, HSBC boosted their price objective on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $606.76.

Insider Transactions at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now owns 1,207 shares in the company, valued at $660,192.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The disclosure for this sale can be found here. Insiders sold 52,277 shares of company stock valued at $29,649,264 over the last three months. Company insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.